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Modification of polycystic kidney disease and fatty acid status libitum pelletized soy protein diet was effective in amel-
by soy protein diet. iorating polycystic kidney disease in the Han:SPRD-cy
Background. Previous studies have demonstrated that soy rat [4]. Animals in the soy protein diet group demon-protein can slow progression of renal injury in the Han:
strated reduced cystic change with both reduced tubularSPRD-cy rat. We undertook a study to establish whether this
proliferation and apoptosis and also a very marked re-benefit was independent of any nutritional deprivation, and
whether or not it was associated with changes in polyunsatu- duction in interstitial fibrosis and inflammation [4]. This
rated fatty acid status that have been previously linked to the model of polycystic kidney disease (PKD) is character-
anti-inflammatory or antineoplastic potential of soy diets. ized by early cystic change, tubular atrophy and progres-Methods. Male Han:SPRD-cy rats were pair fed a 20% ca-
sive interstitial inflammation and fibrosis and an acceler-sein or 20% soy protein diet for six weeks from weaning. Tissue
ated course in male animals [5, 6]. Changes resemblewas harvested for analysis of cystic change, cell proliferation,
macrophage infiltration, and fibrosis. Renal and hepatic tissues many aspects of human PKD, although relative renal
were also harvested for lipid analysis using gas chromatog- volume reaches a maximum value in young adult animals
raphy.
[5]. The responsible gene maps to rat chromosome 8 andResults. Animals thrived on both diets. Soy protein feeding
does not appear to correspond to rodent equivalents ofwas associated with reduced cystic change (4.3 vs. 7.0 mL/kg,
P , 0.0001), epithelial cell proliferation (15.7 vs. 21.0 cells/mm either human PKD1 on chromosome 16 or PKD2 on
epithelium, P , 0.0001), macrophage infiltration (25.3 vs. 43.5 chromosome 4 [7–10]. The model manifests the nonspe-
cells/high-power field, P , 0.0001), and fibrosis (0.6 vs. 1.07 mL/ cific features of dysregulated regeneration and repair
kg, P , 0.0001). The soy diet prevented a significant elevation in
that are characteristic of all models of PKD [11]. Theserum creatinine in diseased versus normal animals. Soy feed-
Han:SPRD-cy rat with its reproducible histologic fea-ing was associated with higher renal and hepatic linoleic acid
content and higher hepatic a-linolenic acid, but lower hepatic tures of interstitial inflammation and fibrosis and clinical
arachidonic acid content. features of hypertension and azotemia may have greater
Conclusions. Isocaloric soy protein feeding ameliorates both value as a reproducible but nonspecific model of progres-epithelial and interstitial changes in the Han:SPRD-cy rat inde-
sive chronic renal injury [12] than as a specific analoguependent of a hypocholesterolemic effect. The histologic benefit
of human PKD.is associated with changes in polyunsaturated fatty acid metab-
olism that may influence both inflammatory and proliferative Dietary soy protein enrichment or substitution may
pathways. modify disease through metabolic consequences of the
protein composition, medicinal effects of phytoestro-
gens, or beneficial effects on plasma cholesterol or poly-
Soy products have been extensively investigated for unsaturated fatty acid (PUFA) metabolism [1]. We have
potential health benefits in atherosclerosis, cancer, and recently demonstrated that a flaxseed-supplemented diet
inflammatory diseases [1]. Soy protein substitution has modifies renal PUFA metabolism in a manner that re-
been effective in ameliorating aging nephropathy in the sults in a significant increase in the ratio of v3 to v6
Fisher 344 rat and renal injury in the 5/6 nephrectomy PUFAs [13]. v3 PUFAs are the precursors of a different,
model [1–3]. In a recent study, we found that an ad less inflammatory series of prostanoids than v6 PUFAs
[14]. Modulation of the dietary intake of v3 and v6
PUFAs has been found to modify the course of experi-Key words: polyunsaturated fatty acid, soy, anti-inflammatory, PKD,
interstitial nephritis. mental chronic renal failure in the dog [15]. Soy protein
feeding has been reported to decrease hepatic activityReceived for publication March 1, 1999
of the enzyme D6 desaturase, the first step in the conver-and in revised form July 22, 1999
Accepted for publication August 20, 1999 sion of the essential v6 PUFA to the eicosanoid precur-
sor, arachidonic acid (20:4v6) [16]. In this report, we 2000 by the International Society of Nephrology
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Table 1. Composition of control and experimental diets day by paired experimental animals. Animals were killed
by exsanguination under pentobarbitone anesthesiaComponent Content % by weight
after six weeks of feeding of test diet and kidney tissueProtein 20 (casein or soy protein)
d-l methionine 0.3 and serum collected for analysis.
Corn starch 52
Dextrose 13 Histology
Cellufil 5
Mineral mix 3.5 Tissue from the left kidney was used for histologic
Vitamin mix 1.0 and immunohistochemical analysis. This tissue was fixed
Choline biturate 0.2
in 10% formalin for 120 minutes prior to embedding inCorn oil 5
Fatty acid composition (% total lipid) paraffin and sectioning at 5 microns. Sections for mea-
16:0 palmitic acid 9.9 surement of cystic volume and qualitative study of renal
18:0 stearic acid 1.7
histology were stained with hematoxylin and eosin. Sec-18:1 (cis-9) oleic acid 26.1
18:1 (cis-11) vaccenic acid 0.5 tions for quantitative analysis of fibrosis were stained
18:2v6 linoleic acid 60.4 using aniline blue alone in adaptation of Masson’s tri-
18:3v3 a-linoleic acid 1.0
chrome stain [17]. This adaptation demonstrates a per-20:0 arachidic acid 0.4
fect concordance of staining with an immunofluorescent
detection of collagen type III in the renal interstitium
[13]. Animals were classified as affected if a single longi-
tudinal cross-section of the kidney contained at least 10describe the results of a study undertaken to test the
hypotheses that the previously observed benefit of soy areas of tubular dilation with an associated increase in
extracellular matrix. High-powered microscopic exami-feeding on progression of Han:SPRD-cy rat PKD is inde-
pendent of protein or caloric deprivation, and that the nation is used in cases of mild disease expression in our
laboratory to insure that lymphatic or empty vascularbenefit is associated with the modification of PUFA me-
tabolism resulting in reduced renal and hepatic content spaces are not being erroneously counted. Two experi-
enced observers (N.B.C. and M.R.O.) confirmed the clas-of v6 PUFAs.
sification.
Cell proliferation was studied using immunohisto-
METHODS
chemical detection of proliferating cell nuclear antigen
Animals (PCNA) as previously reported [4, 13]. Sections were
incubated with a monoclonal anti-PCNA antibodyHan:SPRD-cy rats were obtained from our own breed-
ing colony, which was derived from animals that were (Dako M 0879; Dako A/S, Glostrup, Denmark) at a
dilution of 1:50 for 60 minutes. Secondary detection waskindly provided to us by Dr. Benjamin Cowley (Univer-
sity of Kansas Medical Center, Kansas City, KS, USA). achieved with a Vectastain Elite rat-adsorbed antimouse
IgG kit (Vector Laboratories, Burlingame, CA, USA)All animal procedures and care were examined by the
University of Manitoba Committee on Animal Use and with peroxidase-diaminobenzidine color development.
Macrophages were identified using a monoclonal anti-were certified to be within the guidelines of the Canadian
Council on Animal Care. Surviving male offspring of body against a 90 to 100 kd protein that is expressed on
lysosomal membranes and has many characteristics ofknown Han:SPRD-cy heterozygotes were used in this
study. Two thirds of these animals would be expected the human CD68 antigen (Chemicon MAB1435; Chemi-
con International Inc., Temecula, CA, USA) at a dilutionto be heterozygous, as homozygotes in our colony rarely
survive beyond weaning. of 1:100 for 60 minutes [4, 13]. Secondary detection was
achieved in the same way as for PCNA.Male animals were randomly assigned to treatment or
control groups at weaning (21 days old). Animals re-
Image analysisceived a synthetic diet containing 20% by weight casein
(Harlan Teklad, Madison, WI, USA) or soy protein Image analysis procedures were performed with a sys-
tem consisting of a Cohu high-resolution black and white(RP101 Lab Diet; PMI Nutrition International, Rich-
mond, IA, USA) as the protein source. Both protein camera connected to a computer via a PCVisionPlus
video capture board. Images were captured using thesources were certified to contain only trace (,1%) lipid.
The full composition of the diet, including fatty acid Image Pro software package (Phoenix Biotechnology,
Seattle, WA, USA) [4, 13, 18].analysis, is described in detail in Table 1. The diets were
identical other than protein source, including fatty acid Renal volume was determined using the Cavalieri
principle, as we have described previously [4, 13, 18].composition, confirmed by analysis using the methods
described later in this article. Animals were pair fed with Parallel 2.5 mm sections of the left kidney were cut using
a lucite guide box constructed for this purpose. A videocontrol animals, which were limited to an amount of
food of equal weight to that consumed on the previous image of all sections, including a linear scale, was cap-
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tured and the area of the sections integrated using mod- erozygous Han:SPRD-cy rat, and we no longer measure
these parameters in normal animals.ule 2500 of the Imagemeasure software package (Phoe-
Macrophage numbers and PCNA-positive cells werenix Biotechnology) and renal volume calculated as the
quantitated by counting, using module 2500 of the Im-product of total section area and section thickness.
agemeasure software package [4, 18]. The macrophageMeasurement of relative tubular luminal area, that is,
counts were reported as a mean per high-power videothe fraction of tissue section occupied by tubular lumen,
field (403 microscope objective) with at least 50 fieldswas performed fluorometrically using the IM4100 mod-
counted, corrected for empty areas of the section occu-ule of the Imagemeasure software package (Phoenix Bio-
pied by cysts by multiplying by the reciprocal of thetechnology) using low-power microscopic images cap-
cystic area ratio measurement of that kidney. PCNA-tured via a Cohu high-resolution black and white video
positive cells were reported per millimeter of epithelium.camera. Sections were viewed through a 23 objective
The length of the apical surface of a randomly selectedand Nikon TV relay lens. The samples were illuminated
piece of epithelium was measured from a captured videowith a wide aperture condenser to insure uniform light-
image using the same software module. Cells along theing conditions. The profiling tool within the program was
length of this piece that exhibited the appropriate nu-used to insure uniform lighting of the captured video
clear staining characteristics were then counted. Theimage. A 64 3 64 pixel rectangle was moved in an alter-
score for the kidney was determined as the mean countnating horizontal and vertical path through the section
divided by the mean length from 50 measurements.from a random starting point until 50 measurements
from each of four separate whole kidney tissue cross-
Chemistry
sections had been collected. The inner fluorometric
Serum creatinine, triglycerides, and cholesterol werethreshold was adjusted for each slide to include all gray
determined in serum by spectrophotometric methods us-scale values equal to or greater than open tubular lumen.
ing Sigma kits (Sigma Chemical Co., St. Louis, MO,Some cysts contained eosinophilic debris, but this mate-
USA).rial had gray scale values that were less than that of solid
renal tissues and did not influence results. The outer Gas chromatography
threshold was set to 1 (black) to include all stained areas
Lipids were extracted for gas chromatographic analy-of tissue and the relative tubular luminal area calculated
sis using a modified Folch extraction procedure [20].according to the following formula:
Tissue from the right kidney that had been snap frozen
in liquid nitrogen and stored at 2708C was homogenizedA 5
Xi
Xo in 2:1 chloroform:methanol containing 0.05 mg/mL of
butylated hydroxy-toluene. After centrifugation at 3500
where A is the relative area ratio, Xi is the number of g for 15 minutes at 48C, the supernatant was treated with
pixels within inner threshold, and Xo is the number of an equal volume of 0.73% NaCl and was recentrifuged.
pixels within outer threshold. The aqueous phase was discarded, and the organic phase
An average of 50 measurements from three to five was washed twice with equal volumes of TUP (3:48:47
different sections was used to determine the cyst area chloroform:methanol:water), with each wash followed
ratio. A measurement was accepted if the 95% confi- by a 30-minute centrifugation at 3500 g at 48C, after
dence intervals of the mean were within 2% of the mean. which the theoretical upper phase and interphase layers
Renal fibrous volume was measured in a similar way, were removed by siphoning. The remaining organic layer
using the proportion of section areas that had taken up was dried under nitrogen at 308C, resuspended in 100
aniline blue stain as measured in densitometry mode of mL of 2:1 chloroform:methanol, and stored in a glass
module 4100 of the Imagemeasure software package. In microvial under nitrogen gas. Measurement of fatty acid
densitometry mode, the thresholds are reversed with the content was performed on a Varian Star 3400 instrument,
outer threshold set to 255 (white) and the inner threshold using a J & W DB 225 30 meter column, after methylation
set 1 gray scale unit over the actual measured value of of the sample and addition 100 mL of C17:0 (heptadeca-
an area of interstitial aniline blue staining. The product noic acid) as an internal standard. Chromatographs were
of the proportion and the reference renal volume, cor- integrated using Varian GC Star software, version 3.0.
rected to body weight, gives the final volume occupied
Statistical analysisby either renal cyst volume or renal fibrous tissue [19].
Although normal tubular lumina and Bowman’s capsules Data collected from both normal and PKD animals
and basement membranes make a small contribution were analyzed using one-way analysis of variance with
to the measurements of cyst volume and renal fibrous the Bonferroni test or Kruskal–Wallis test where appro-
volume, respectively, the values in normal kidneys are priate for selected post hoc comparisons if P , 0.05
in the analysis of variance, using the Prism2 softwaretwo orders of magnitude smaller than those seen in het-
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Table 2. Physical and renal histologic parameters of normal or Han:SPRD-cy rats fed casein or soy protein-based diets
Normal PKD
Casein Soy P Casein Soy P
N 11 7 19 23
Weight g 326 (33) 312 (12) NS 315 (17) 317 (26) NS
Renal volume ml/kg body wt 5.3 (0.5) 5.1 (0.4) NS 13.6 (1.4) 10.7 (1.8) ,0.001
Cyst volume ml/kg body wt N/A N/A N/A 7.0 (0.8) 4.3 (1.4) ,0.0001
Renal fibrous volume ml/kg body wt N/A N/A N/A 1.07 (0.19) 0.60 (0.15) ,0.0001
PCNA score cells/mm epithelium ,1.0 ,1.0 NS 21.0 (3.1) 15.7 (2.4) ,0.0001
Macrophage count
cells/high power video field ,1.0 ,1.0 NS 43.5 (10.8) 25.5 (7.8) ,0.0001
Results are expressed as mean values with standard deviations in parentheses. N/A is not available and NS is not significant.
package (Graphpad Software, San Diego, CA, USA).
Data collected only from PKD animals were compared
using Student’s t-test with the Welch correction using
the same software package.
RESULTS
At tissue harvest, 42 of 60 animals included in the
study were found to PKD. A total of 11 animals without
renal disease and 19 animals with PKD received the
control diet, and 7 healthy animals and 23 with PKD
received the soy protein-based diet. All animals thrived
irrespective of disease or diet status, and weights were
consistent with rats of the same age fed a standard chow
(Table 1).
The soy protein diet was associated with a significant
reduction in renal volume in animals with PKD but no
difference in renal volume in animals without renal dis-
ease (Table 2). Cyst volume in animals with PKD was
significantly reduced by the soy diet. This reduction in
cyst volume was associated with changes in markers of
both tubular and interstitial remodeling, including
PCNA score, renal fibrous volume, and interstitial mac-
rophage count (Table 2). Representative examples of
the histologic change are shown in Figure 1 (control)
and Figure 1B (soy).
The soy protein diet did not influence serum creati-
nine, triglycerides, or cholesterol in normal animals (Ta-
Fig. 1. (A) Kidney section from Han:SPRD-cy rat fed control (20%
ble 3). The difference in serum creatinine between ani- casein diet) at nine weeks of age (hematoxylin and eosin, 340). (B)
Kidney section from Han:SPRD-cy rat fed 20% soy protein diet at 9mals with PKD on control or soy diet was not significant,
weeks of age (hematoxylin and eosin, 340). The photomicrographbut PKD animals on the control diet had significantly
demonstrates reduced cystic change with preservation of areas of normal
higher serum creatinines than normal animals on the renal architecture, reduced interstitial inflammatory infiltrates, and peri-
tubular fibrosis.same diet (P , 0.01), whereas PKD was not associated
with a significant rise in serum creatinine in soy-fed ani-
mals, implying a slower decline in renal function. PKD
animals demonstrated no difference in triglycerides or
PUFAs such as arachidonic acid, nor with a shift in thecholesterol attributable to diet.
v3:v6 ratio. Soy protein feeding was associated withGas chromatographic analysis of the lipid extracts
similar enrichment of linoleic acid in the liver, althoughfrom renal tissue revealed a relative enrichment of the
to a greater degree, in both normal and PKD animals18C v6 PUFA, linoleic acid, which was significant in
(Table 5). Hepatic content of arachidonic acid, however,animals with PKD (Table 4). This was not, however,
associated with higher proportions of longer chain v6 was significantly lower in both normal and PKD soy-fed
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Table 3. Serum chemistry of normal or Han:SPRD-cy rats fed casein or soy protein-based diets
Normal PKD
Casein Soy P Casein Soy P
N 11 7 19 23
Creatinine lmol/L 82.5 (11.8) 83.7 (7.6) NS 104.6 (33.2)a 96.7 (19.8) NS
Cholesterol mmol/L 2.06 (0.86) 1.65 (0.56) NS 2.15 (1.04) 1.93 (0.71) NS
Triglycerides mmol/L 1.04 (0.48) 0.47 (0.28) NS 0.71 (0.49) 0.80 (0.46) NS
Results are expressed as mean values with standard deviations in parentheses.
a Significantly greater than normal animals receiving the same diet, P , 0.01
Table 4. Fatty acid content of kidneys from normal or Han:SPRD-cy rats fed casein or soy protein-based diets
Normal PKD
Casein Soy P Casein Soy P
N 11 7 19 23
16:0 22.9 (3.2) 21.5 (1.7) NS 22.0 (1.5) 21.7 (1.4) NS
16:1 2.42 (2.26) 1.47 (1.63) NS 1.28 (1.15) 1.52 (1.19) NS
18:0 13.5 (4.0) 14.7 (3.6) NS 15.2 (2.4) 13.7 (3.0) NS
18:1a 14.8 (9.9) 11.7 (7.4) NS 10.5 (4.7) 12.8 (5.3) NS
18:1b 2.52 (0.36) 2.18 (0.21) ,0.05 2.78 (0.16) 2.30 (0.21) ,0.001
18:2 v6 12.5 (2.7) 15.7 (3.3) NS 11.6 (2.4) 16.6 (4.9) ,0.001
18:3 v3 0.073 (0.091) 0.128 (0.155) NS 0.051 (0.095) 0.150 (0.146) NS
20:0 0.123 (0.062) 0.181 (0.051) NS 0.377 (0.110) 0.239 (0.100) ,0.001
20:1 0.101 (0.070) 0.132 (0.062) NS 0.291 (0.054) 0.235 (0.051) ,0.05
20:2 v6 0.319 (0.112) 0.563 (0.141) NS 0.781 (0.192) 0.779 (0.203) NS
20:3 v6 0.639 (0.291) 0.668 (0.229) NS 0.617 (0.128) 0.611 (0.178) NS
20:4 v6 24.3 (10.9) 24.8 (8.0) NS 25.6 (5.1) 22.4 (6.7) NS
22:0 0.418 (0.055) 0.482 (0.066) NS 0.700 (0.138) 0.532 (0.122) ,0.001
22:1 0.514 (0.426) 0.318 (0.438) NS 0.341 (0.408) 0.375 (0.385) NS
22:2 0.163 (0.123) 0.184 (0.088) NS 0.205 (0.074) 0.191 (0.150) NS
22:3 v6 0.635 (0.254) 0.586 (0.186) NS 1.031 (0.267) 0.718 (0.270) ,0.01
22:5 v3 0.103 (0.97) 0.169 (0.080) NS 0.204 (0.78) 0.231 (0.131) NS
22:6 v3 0.997 (0.458) 1.15 (0.383) NS 0.899 (0.212) 1.06 (0.356) NS
24:0 1.38 (0.66) 1.57 (0.65) NS 1.91 (0.52) 1.38 (0.54) ,0.05
v3:v6 ratio 0.029 (0.006) 0.033 (0.004) NS 0.030 (0.006) 0.035 (0.009) NS
Results are expressed as a mean percentage of total lipids with standard deviations in parentheses, except the v3:v6 ratio, which is calculated from the listed
mean values of each class of fatty acid.
a (cis-9) oleic acid
b (cis-11) vaccenic acid
animals despite the apparent increased availability of based pellets. We therefore undertook this study using a
powdered diet with strict control of the amount ingested.its precursor. Unlike the kidney, soy feeding was also
Our results confirm that soy protein substitution doesassociated with increased hepatic content of a-linolenic
modify all histologic components of expression ofacid (18:3v3) and also docosopentaenoic acid (22:5v3),
Han:SPRD-cy rat PKD, while maintaining normalalthough the total v3:v6 ratio was not changed because
weight gain in the animals.of the relative enrichment of linoleic acid (18:2v6).
Perhaps the most striking feature of soy protein-modi-
fied disease in this model is the extent to which all of
DISCUSSION the components of renal remodeling, proliferation, in-
Our results confirm that soy protein substitution atten- flammation, and fibrosis are modified. Soy diets have
uates the rate of progression of all aspects of Han: been advocated in humans for their hypocholesterolemic
SPRD-cy rat PKD. Similar benefits have been observed effect [21], and cholesterol metabolism or synthesis has
in the Fisher rat model of aging nephropathy and the 5/ been implicated in models of renal injury, including the
6 nephrectomy rat model of chronic renal failure, im- Han:SPRD-cy rat [22, 23]. Unlike our earlier study, we
plying a benefit that may be generalized to other forms did not observe a hypocholesterolemic effect of the soy
of renal injury. In our previous ad libitum soy protein- diet when using a cholesterol-free isocaloric feeding re-
feeding study, improvement in Han:SPRD-cy rat PKD gime, a finding confirmed by Madani et al [24]. That
was also associated with impaired weight gain [4]. We group found that soy feeding was associated with in-
creased HMG-CoA reductase activity, the enzyme phar-believe that this was due to the hard texture of the soy-
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Table 5. Fatty acid content of liver from normal or Han:SPRD-cy rats fed casein or soy protein-based diets
Normal PKD
Casein Soy P Casein Soy P
N 11 7 19 23
16:0 23.3 (0.9) 21.9 (0.8) ,0.05 21.5 (1.1) 21.8 (1.1) NS
16:1 2.53 (1.57) 0.96 (0.35) ,0.01 1.34 (0.61) 1.03 (0.59) NS
18:0 9.13 (1.59) 6.43 (1.00) NS 11.66 (1.88) 9.24 (3.22) ,0.05
18:1a 17.4 (2.3) 17.0 (1.6) NS 13.7 (1.8) 13.3 (4.1) NS
18:1b 5.20 (0.68) 3.34 (0.36) ,0.01 3.72 (0.51) 3.35 (1.68) NS
18:2 v6 20.2 (2.7) 31.8 (1.5) ,0.001 22.1 (1.7) 28.0 (5.3) ,0.001
18:3 v6 0.33 (0.05) 0.27 (0.07) NS 0.35 (0.05) 0.29 (0.13) NS
18:3 v3 0.27 (0.15) 0.51 (0.09) ,0.01 0.18 (0.10) 0.42 (0.16) ,0.001
20:1 0.21 (0.08) 0.36 (0.05) ,0.01 0.23 (0.04) 0.28 (0.06) NS
20:2 v6 0.40 (0.13) 0.80 (0.28) ,0.001 0.57 (0.09) 0.80 (0.22) ,0.01
20:3 v6 0.44 (0.05) 0.50 (0.10) NS 0.45 (0.06) 0.54 (0.14) NS
20:4 v6 15.1 (2.4) 10.2 (1.7) ,0.05 18.1 (1.9) 14.1 (4.5) ,0.01
22:0 0.43 (0.09) 0.38 (0.06) NS 0.39 (0.09) 0.37 (0.08) NS
22:3 v6 0.96 (0.08) 1.68 (0.13) ,0.001 1.20 (0.12) 1.55 (0.30) ,0.001
22:4 1.54 (0.44) 1.49 (0.13) NS 1.61 (0.24) 1.57 (0.30) NS
22:5 v3 0.31 (0.04) 0.50 (0.06) ,0.001 0.35 (0.03) 0.52 (0.08) ,0.001
22:6 v3 1.79 (0.36) 1.51 (0.35) NS 2.08 (0.34) 2.20 (0.83) NS
24:0 0.18 (0.11) 0.14 (0.10) NS 0.19 (0.13) 0.27 (0.37) NS
v3:v6 ratio 0.063 (0.011) 0.056 (0.009) NS 0.061 (0.008) 0.070 (0.022) NS
Results are expressed as a mean percentage of total lipids with standard deviations in parentheses, except the v3:v6 ratio, which is calculated from the listed
mean values of each class of fatty acid.
a (cis-9) oleic acid
b (cis-11) vaccenic acid
macologically inhibited in the study of Gile et al, who have been found to have direct actions in the regulation
of cell proliferation.noted amelioration of Han:SPRD-cy rat PKD with lova-
statin therapy [23]. That group hypothesized that lovas- We believe that the alterations in renal and hepatic
fatty acid content that we have observed imply an alter-tatin therapy reduced the production of farnesyl pyro-
phosphate, a critical cofactor in G-protein–dependent ation in PUFA metabolism that may contribute to the
observed degrees of inflammation and epithelial prolifer-signaling pathways. These pathways are involved in the
activity of peptide growth factors, also implicated in the ation. Lindholm has previously noted that soy protein
ingestion in rats was associated with decreased hepaticprogression of chronic renal disease, particularly PKD
[25]. We believe that it is unlikely that cholesterol-related D6 desaturase activity, the first enzymatic step in the
conversion of linoleic acid to arachidonic acid, orpathways are involved in the observed benefit to renal
disease. The hypocholesteremic effect observed in our a-linolenic acid to eicosapentenoic acid [16]. The nature
of this decreased activity is subject to some controversy,previous study was probably due to differences in total
caloric intake. as the activity of the enzyme is dependent not on only
the absolute amount of enzyme present, but also theSoy phytoestrogens have been implicated in beneficial
effects on atherosclerosis and cancer risk [26–28]. The configuration of the protein with respect to other compo-
nents of an essential electron transport system [31]. Kobagender-dependent nature of Han:SPRD-cy rat disease
[29], seen to a lesser extent with human disease [30], et al found both an alteration of fluidity of the micro-
somal membrane that could alter the interaction betweensuggests that these agents, which have been demon-
strated to be both antiproliferative and anti-inflamma- the components of the enzymatic complex and a de-
creased expression of enzyme protein [32]. Montgomerytory in nonrenal tissues, may play a role.
The breadth of histologic effect of this dietary inter- and Cinti found evidence of desaturase activity in micro-
somal fractions prepared from rat renal cortex [33].vention encourages speculation that the diet influences
cellular biochemistry at a very basic level common to Chern and Kinsella have identified significant D6 desa-
turase activity in cultured rat kidney cells of an indeter-many cell phenotypes. Although possible explanations
are legion, in this study, we chose to focus on PUFA minate phenotype [34]. Similar evidence of D5 and D6
desaturase activity has been found in LLC-PK cells [35]metabolism, as soy protein has been known to alter activ-
ity in this pathway independent of dietary lipid content. and renal cortex from SHR rats [36], although the pheno-
type of the cell responsible has not been confirmed. Re-Modification of this pathway has been demonstrated to
influence inflammation in a variety of tissues, including nal PUFA content may not, therefore, simply be deter-
mined by hepatic release of PUFA. Our results arekidney. Certain PUFA, particularly arachidonic acid,
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consistent with reduced hepatic D6 desaturase activity tive and inflammatory indices were highest in the animals
in either or both organs. Such a reduction would account with lower renal linoleic acid content. Aukema et al
for both accumulation of linoleic and linolenic acids, as noted that an alteration of diet lipid source and disease
unused substrates and consequently reduced arachidonic expression in the pcy mouse was associated with an alter-
acid production. We did not identify an accumulation of ation in phospholipid composition of the kidney [44]. A
g-linolenic acid (18:3v6) in either tissue, which would potential role for arachidonic acid-mediated changes in
have been expected if inhibition of the elongase was phospholipase activity is supported by Jiao et al, who
present [37]. We were unable to identify significant quan- found that arachidonic acid mediated angiotensin II re-
tities of eicosopentenoic acid in any tissues and are thus ceptor interactions with mitogen-associated protein ki-
unable to comment on the subsequent metabolism of nases in renal epithelial cells [45]. A relationship between
a-linolenic acid. Furthermore, neither our experimental cystic formation and such angiotensin II-dependent
design nor prior knowledge can discriminate whether pathways has been implied in the Han:SPRD-cy rat by
the apparent difference in activity is due to decreased other studies [46, 47]. Cui and Douglas have also shown
activity of the enzymes within a cell type or due to differ- that arachidonic acid mediates mitogen-associated pro-
ences in content of a cell type, for example, fibroblasts, tein kinases in renal epithelial cells independently of
that may express the enzyme. eicosanoid synthesis [48].
The potential for lipid sources rich in a-linolenic acid This study confirms that soy protein modifies the ex-
to modify renal injury has been the subject of growing pression of Han:SPRD-cy rat PKD in a manner that is
interest and provides support for the hypothesis that independent of any caloric or other nutritional defi-
soy protein reduction of renal injury is lipid mediated. ciency. Although the design of our study does not estab-
Increasing dietary a-linolenic acid content is one of the lish a cause and effect relationship between changes in
simplest strategies for reduction of arachidonic acid and PUFA metabolism and altered disease progression, the
other v6 PUFA, through competition with linoleic acid complex interrelationships between protein intake and
for D6-desaturase and subsequent enzyme steps in fatty lipid metabolism mandate careful future study of possi-
acid synthesis [37]. Ingram et al have demonstrated that ble effector pathways. Ultimate proof may require selec-
a flax oil supplementation, a rich dietary source of tive dietary lipid substitution or pharmacologic blockade
a-linolenic acid, slows renal injury in the 5/6 rat nephrec- of enzymes that are, as yet, beyond our technology. Until
tomy model [38]. Whole flaxseed supplementation, such data are gathered and the precise mechanisms of
which also results in replacement of linoleic with the observed benefits of soy protein substitution are un-
a-linolenic acid, reduces injury in murine lupus and the derstood, caution must be exercised in extrapolating
Han:SPRD-cy rat [13, 39]. Fish oil supplements, which these results to the management of human disease.
are also rich sources of v3 PUFA, have been advocated
as beneficial in IgA nephropathy, albeit with consider-
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